Quantcast

Latest Triptans Stories

2014-08-05 16:27:40

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights -- Total company net revenues of $28.6 million. -- Net NUEDEXTA® sales of $26.5 million. -- Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with...

2014-06-24 08:31:20

ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM) Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56(th) Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel...

2014-06-19 23:09:34

MarketReportsOnline.com adds "Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19)" report to its research store. Dallas, Texas (PRWEB) June 19, 2014 Acute migraine treatment market is dominant by Triptans and most of them are available as pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas rizatriptan and zolmitriptan are available as tablets that dissolve in mouth. In next 5-10 years, cost of migraine drugs is...

2014-06-10 08:30:15

AVP-825, Using OptiNose's Patented Bi-Directional(TM) Breath Powered(TM) Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest Dose of Oral Sumatriptan YARDLEY, Pa., June 10, 2014 /PRNewswire/ -- OptiNose today announced that the COMPASS trial, a head-to-head comparison of the investigational treatment AVP-825 to sumatriptan tablets, currently the most widely used prescription medication for migraine, met...

2014-06-10 04:22:17

--Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment-- ALISO VIEJO, Calif., June 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary...

2014-05-19 08:27:47

-Addition of product to Specialty Pharmaceuticals portfolio expected to be immediately accretive to adjusted diluted earnings per share DUBLIN, May 19, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel(®) DosePro(®) (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash...

2014-04-28 08:27:50

New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66(th) American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology,...

2014-04-24 08:33:37

-- Addition of product to Specialty Pharmaceuticals portfolio expected to be immediately accretive to adjusted diluted earnings per share DUBLIN, April 24, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have acquired worldwide rights to Sumavel(®) DosePro(®) (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. Under the terms of the agreement, Endo...

2014-04-11 08:24:31

PITTSBURGH, April 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA(®), which is used to treat acute...

2014-04-08 08:29:08

CARDIFF, Calif., April 8, 2014 /PRNewswire/ -- NI Research has released the April issue of NeuroPerspective, which reviews and assesses migraine therapeutics in development. Migraine is the most common of all neurological disorders. Based on epidemiological studies done in the US and Europe during the 1990s, approximately 12.6% of the population experiences migraine in a given year, with 18% suffering from migraine at some point in their lifetimes. It is estimated that there are 36...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related